Amplimmune
Latest round
- Series A
Last raised
- Mar 2007
Total raised
- $5.9M
Investors
- 2
About Amplimmune
Amplimmune, Inc.Amplimmune, Inc. focuses on the development of immune-modulating therapies. Established in Rockville, US, the company was acquired by MedImmune, Inc. in August 2013 for an initial USD 225 million, with potential deferred payments of up to USD 275 million based on development milestones.Amplimmune, Inc. specializes in creating biological products that harness the immune system to combat diseases such as cancer.88 mn.Looking ahead, Amplimmune, Inc. The planned expansion includes targeting key regions in North America and Europe.
Who invested in Amplimmune
2 investors across 1 round
See all investors in Amplimmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 31, 2007
Amount
$5.9M
Investors
Questions about Amplimmune
Who invested in Amplimmune?
Amplimmune has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Amplimmune raised?
Amplimmune has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Amplimmune last raise money?
Amplimmune's most recent round on record is a Series A, in Mar 2007.
What does Amplimmune do?
Amplimmune is a biotechnology company.
Where is Amplimmune headquartered?
Amplimmune is headquartered in Rockville, US.
Which VCs invest in companies like Amplimmune?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Amplimmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Amplimmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.